Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

314
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
314
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

79
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
79

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent dual C-H isotopic fractionation pattern during anaerobic biodegradation of toluene within Aromatoleum species under nitrate-reducing conditions.

Environmental pollution (Barking, Essex : 1987)·2024
Same author

Redox-Polymer-Wired [NiFeSe] Hydrogenase Variants with Enhanced O<sub>2</sub> Stability for Triple-Protected High-Current-Density H<sub>2</sub> -Oxidation Bioanodes.

ChemSusChem·2020
Same author

Introduction to the application of QbD principles for the development of monoclonal antibodies.

Biologicals : journal of the International Association of Biological Standardization·2016
Same author

Determination of critical quality attributes for monoclonal antibodies using quality by design principles.

Biologicals : journal of the International Association of Biological Standardization·2016
Same author

Establishing a control system using QbD principles.

Biologicals : journal of the International Association of Biological Standardization·2016
Same author

Profile of the Patient Who Refuses to Participate in the Expert Patients Program.

Qualitative health research·2014

Related Experiment Video

Updated: Mar 17, 2026

Production and Targeting of Monovalent Quantum Dots
10:16

Production and Targeting of Monovalent Quantum Dots

Published on: October 23, 2014

26.1K

QbD implementation and Post Approval Lifecycle Management (PALM).

Ettore Ohage1, Raquel Iverson2, Lynne Krummen2

  • 1Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.

Biologicals : Journal of the International Association of Biological Standardization
|July 25, 2016
PubMed
Summary

Quality by Design (QbD) enhances pharmaceutical development by proactively designing manufacturing processes. A Post Approval Lifecycle Management (PALM) plan manages risks and ensures consistent product quality during commercial manufacturing.

Keywords:
Change controlDesign spaceImplementationLifecycle managementProcess monitoringQbD

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K

Related Experiment Videos

Last Updated: Mar 17, 2026

Production and Targeting of Monovalent Quantum Dots
10:16

Production and Targeting of Monovalent Quantum Dots

Published on: October 23, 2014

26.1K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K

Area of Science:

  • Pharmaceutical Manufacturing
  • Biotechnology
  • Regulatory Science

Background:

  • Quality by Design (QbD) is a global regulatory initiative aimed at improving pharmaceutical development.
  • ICH Q8-11 guidelines provide principles for QbD implementation in pharmaceutical development.
  • Understanding product and process knowledge is crucial for consistent manufacturing.

Purpose of the Study:

  • To describe the implementation of a control strategy for monoclonal antibody manufacturing using QbD principles.
  • To outline the use of a Design Space for routine commercial manufacturing.
  • To detail the Post Approval Lifecycle Management (PALM) plan for managing post-approval risks.

Main Methods:

  • Utilizing an integrated set of risk assessments to gain product and process knowledge.
  • Defining a Design Space for commercial manufacturing of a recombinant monoclonal antibody.
  • Developing a PALM plan as a regulatory agreement for post-approval product lifecycle management.

Main Results:

  • The described approach provides an overview of product and process knowledge for monoclonal antibody production.
  • Implementation of a control strategy including a Design Space ensures consistent product performance.
  • The PALM plan facilitates regulatory agreement on monitoring and managing risks post-approval.

Conclusions:

  • QbD principles, integrated risk assessments, and a robust control strategy are essential for consistent pharmaceutical manufacturing.
  • The Design Space and PALM plan are key components for managing commercial manufacturing and post-approval lifecycle.
  • This framework supports the proactive design and control of pharmaceutical processes to ensure product quality and regulatory compliance.